John F. Thompson

About John F. Thompson

Technology expert and problem-solving leader with strategic, technical and supervisory experience in diagnostics (cancer and rare disease), clinical genetics, next-generation sequencing instrument development, gene therapy, and pharmaceutical research and development• Precision medicine for cancer, rare disease, cardiovascular and metabolic disease therapies• Created superior clinical NGS assays for diagnosing rare pediatric diseases in CLIA, ISO15189, New York-state approved lab• Developed novel applications at two single-molecule, genomic analysis companies using SBS and nanopore/nanochannel technologies• Identified novel therapeutic targets and the genetic basis of drug response and drug-induced adverse events• Developed wide range of high throughput assays for drug discovery using small molecule binding, reporter genes, protein-protein interactions, and FRET• Spearheaded GWAS for cardiovascular and metabolic diseases and response to statins• Applied translational genomics technologies such as RNA-Seq, genetic variant detection with NGS and qPCR, ChIP-Seq, microarrays• Worked with experts in oncology, plant genetics, metagenomics/microbiomes, ancient DNA to develop NGS applications suited to needs

Experience

1. Principal Application Scientist

   Nabsys

   Jun 2023 — Present · Providence, RI, US

Education

• University of California, Berkeley

  PhD, Biophysical Chemistry

  1978 — 1982

• Yale University

  BS, Chemistry

  1975 — 1978

Skills

• Genomics
• Dna Analysis
• Sequencing
• Molecular Biology
• Genetics
• Drug Discovery
• Diagnostics
• Cell Based Assays
• Biotechnology
• Personalized Medicine
• Genetic Testing
• High Throughput Screening
• Dna Sequencing
• Dna
• In Vitro
• Lifesciences
• Biochemistry
• Cell
• Microarray
• Drug Development
• Proteomics
• Assay Development
• Oncology
• Product Development
• Translational Medicine